Evidence map›Paper›PMID 39843169›Full record

Trial reportBMJ (Clinical research ed.)2025

Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.

Yuejun Liu, Ying Chen, Jianhua Ma, Jiayang Lin, Changqin Liu, Xuejun Li, Yong Xu, Hongyu Kuang, Lixin Shi, Yaoming Xue and 13 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ (Clinical research ed.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04004793. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04004793 phase4completed

Effect of Dapagliflozin for Remission of Type 2 Diabetes Mellitus: A Multicenter, Randomized, Placebo-Controlled Trial

Ran2020Enrolled328Registered outcomes11Posted comparisons0ConditionsType 2 DiabetesArmsDapagliflozin 10 MG Oral Tablet, Intensive Lifestyle Intervention, Placebo Oral Tablet
Open the trial in the graph
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Clinical and Metabolic Characteristics of Spontaneous Remission in Type 2 Diabetes: A Real-World Study from South India.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Observational
  13. Article
  14. The future of nephrology in 2050.Future healthcare journal · 2025
    Article
  15. Review
  16. Recent progress of remission in type 2 diabetes.Therapeutic advances in endocrinology and metabolism · 2025
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Yuejun LiuMinistry of Education Key Laboratory of Metabolism and Molecular Medicine, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Ying ChenMinistry of Education Key Laboratory of Metabolism and Molecular Medicine, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Jianhua MaDepartment of Endocrinology, Nanjing First Hospital, Nanjing, China.
Jiayang LinDepartment of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Changqin LiuDepartment of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Xuejun LiDepartment of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Yong XuDepartment of Diabetes and Endocrinology, Affiliated Hospital of Southwest Medical University, Luzhou, China.
Hongyu KuangDepartment of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Lixin ShiDepartment of Endocrinology and Metabolism, Affiliated Hospital of Guizhou Medical University, Guizhou, China.
Yaoming XueDepartment of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Bo FengDepartment of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Dalong ZhuDepartment of Endocrinology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
Guang WangDepartment of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Jinkui YangDepartment of Endocrinology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Xinhua XiaoDepartment of Endocrinology, Peking Union Medical College Hospital, Beijing, China.
Xuefeng YuDepartment of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Jiaqiang ZhouDepartment of Endocrinology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yuqian BaoDepartment of Endocrinology and Metabolism, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, China.
Qing SuDepartment of Endocrinology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Minzhi LyuDepartment of Biostatistics, Zhongshan Hospital of Fudan University, Center of Evidence-based Medicine, Fudan University, Shanghai, China.
Xiaomu LiMinistry of Education Key Laboratory of Metabolism and Molecular Medicine, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Huijie ZhangDepartment of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiaoying LiMinistry of Education Key Laboratory of Metabolism and Molecular Medicine, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-9383-5757

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the effect of dapagliflozin plus calorie restriction on remission of type 2 diabetes.

designMulticentre, double blind, randomised, placebo controlled trial.

setting16 centres in mainland China from 12 June 2020 to 31 January 2023.

participants328 patients with type 2 diabetes aged 20-70 years, with body mass index >25 and diabetes duration of <6 years.

interventionsCalorie restriction with dapagliflozin 10 mg/day or placebo.

main outcome measuresPrimary outcome: incidence of diabetes remission (defined as glycated haemoglobin <6.5% and fasting plasma glucose <126 mg/dL in the absence of all antidiabetic drugs for at least 2 months); secondary outcomes: changes in body weight, waist circumference, body fat, blood pressure, glucose homoeostasis parameters, and serum lipids over 12 months.

resultsRemission of diabetes was achieved in 44% (73/165) of patients in the dapagliflozin group and 28% (46/163) of patients in the placebo group (risk ratio 1.56, 95% confidence interval (CI) 1.17 to 2.09; P=0.002) over 12 months, meeting the predefined primary endpoint. Changes in body weight (difference -1.3 (95% CI -1.9 to -0.7) kg) and homoeostasis model assessment of insulin resistance (difference -0.8, -1.1 to -0.4) were significantly greater in the dapagliflozin group than in the placebo group. Likewise, body fat, systolic blood pressure, and metabolic risk factors were significantly more improved in the dapagliflozin group than in the placebo group. In addition, no significant differences were seen between the two groups in the occurrence of adverse events.

conclusionThe regimen of dapagliflozin plus regular calorie restriction achieved a much higher rate of remission of diabetes compared with calorie restriction alone in overweight or obese patients with type 2 diabetes.

trial registrationClinicalTrials.gov NCT04004793.

Indexed as

Benzhydryl CompoundsCaloric RestrictionDiabetes Mellitus, Type 2GlucosidesSodium-Glucose Transporter 2 InhibitorsAdultAgedBlood GlucoseBody Mass IndexChinaDouble-Blind MethodFemaleGlycated HemoglobinHumansMaleMiddle AgedBenzhydryl CompoundsBlood GlucosedapagliflozinGlucosidesGlycated HemoglobinSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID39843169
PMCPMC11752448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.